Saturday, September 18, 2021 10:31:07 AM
Last week? Last week is nothing at the scale of the Cytodyn's pump & dump cycles.
The Cytodyn price has been the following for the vast majority of investors:
Notice a pattern? Pumps followed by larger dumps. The exact same pattern is unfolding as we speak. Nader Pourhassan « meeting » his hotel lobby manager in Manilla or sending fake data to the regulator won’t change this. Exactly as it didn’t change anything before to the unavoidable dumps. Weekly dumps, monthly dumps, quarterly dumps.
The only reason the dumps are not immediate is because the borrow is limited, preventing short-sellers from selling more. But once the private investors used by Nader to draw funds transfer their new discounted shares to their brokers (like they did EVERY TIME BEFORE), it floods the market with sell orders plus bumps up the borrow allowing shortsellers to double the downside fall. A double impact. This is what has happened EVERY time before and will happen there too.
Additionally, all the SEC filings show that the company is bankrupting as we speak. They have stopped paying critical contractors (like their CRO) and are burning + reimbursing on average around $1 million PER DAY for this ongoing accounting exercise. This is killing them as the SEC has blocked their requests to issue new shares to investors. They are trapped and can't even wait for a couple weeks.
Until then, i enjoy this shake up! Cherry on the cake for me
The Cytodyn price has been the following for the vast majority of investors:
Notice a pattern? Pumps followed by larger dumps. The exact same pattern is unfolding as we speak. Nader Pourhassan « meeting » his hotel lobby manager in Manilla or sending fake data to the regulator won’t change this. Exactly as it didn’t change anything before to the unavoidable dumps. Weekly dumps, monthly dumps, quarterly dumps.
The only reason the dumps are not immediate is because the borrow is limited, preventing short-sellers from selling more. But once the private investors used by Nader to draw funds transfer their new discounted shares to their brokers (like they did EVERY TIME BEFORE), it floods the market with sell orders plus bumps up the borrow allowing shortsellers to double the downside fall. A double impact. This is what has happened EVERY time before and will happen there too.
Additionally, all the SEC filings show that the company is bankrupting as we speak. They have stopped paying critical contractors (like their CRO) and are burning + reimbursing on average around $1 million PER DAY for this ongoing accounting exercise. This is killing them as the SEC has blocked their requests to issue new shares to investors. They are trapped and can't even wait for a couple weeks.
Until then, i enjoy this shake up! Cherry on the cake for me
Recent CYDY News
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
